الاتحاد الأوروبي -
الرومانية -
EMA (European Medicines Agency)
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantle-cell - agenți antineoplazici - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
مولدافيا -
الرومانية -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
filgrastim 300 mcg/0,5 ml soluţie injectabilă în seringă preumplută
farmina srl Îcs - filgrastimum - soluţie injectabilă în seringă preumplută - 300 mcg/0,5 ml
مولدافيا -
الرومانية -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
filgrastim 300 mcg/ml soluţie injectabilă/perfuzabilă
farmina srl Îcs - filgrastimum - soluţie injectabilă/perfuzabilă - 300 mcg/ml
الاتحاد الأوروبي -
الرومانية -
EMA (European Medicines Agency)
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agenți antineoplazici - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
مولدافيا -
الرومانية -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
accofil 48 mu/0,5 ml soluție injectabilă sau perfuzabilă în seringă preumplută
accord healthcare s.l.u. - filgrastimum - soluție injectabilă sau perfuzabilă în seringă preumplută - 48 mu/0,5 ml
مولدافيا -
الرومانية -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
accofil 30 mu/0,5 ml soluție injectabilă sau perfuzabilă în seringă preumplută
accord healthcare s.l.u. - filgrastimum - soluție injectabilă sau perfuzabilă în seringă preumplută - 30 mu/0,5 ml
الاتحاد الأوروبي -
الرومانية -
EMA (European Medicines Agency)
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - mielom multiplu - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
مولدافيا -
الرومانية -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
neutromax 30 m u.i. 300 mcg/ml soluţie injectabilă
biosidus s.a. - filgrastimum - soluţie injectabilă - 300 mcg/ml
رومانيا -
الرومانية -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
thiotepa fresenius kabi 100 mg
fresenius kabi deutschland gmbh - germania - thiotepum - pulb. pt. conc. pt. sol. perf. - 100mg - agenti alchilanti agenti alchilanti
رومانيا -
الرومانية -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
thiotepa fresenius kabi 15 mg
fresenius kabi deutschland gmbh - germania - thiotepum - pulb. pt. conc. pt. sol. perf. - 15mg - agenti alchilanti agenti alchilanti